Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Oct 8;34(41):13571-3.
doi: 10.1523/JNEUROSCI.3196-14.2014.

Neuroinflammation mediates synergy between cerebral ischemia and amyloid-β to cause synaptic depression

Walter Swardfager  1 , Madelaine Lynch  2 , Sonam Dubey  2 , Paul M Nagy  3
Affiliations
Comment

Neuroinflammation mediates synergy between cerebral ischemia and amyloid-β to cause synaptic depression

Walter Swardfager et al. J Neurosci. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Possible relationships between ischemia, amyloid-β, and neuroinflammation. Origlia and colleagues (2014) demonstrated that ischemia can induce amyloid-β synthesis, microglial RAGE-dependent JNK activation, p38MAPK activation, and IL-1β release that results in synaptic dysfunction. They suggest a feedforward loop whereby the presence of amyloid-β during ischemia exacerbates neuroinflammation, which promotes additional amyloid-β production. To close this loop, further work should investigate the contributions of microglial, astrocyte, neuronal, and endothelial RAGE, and neuroinflammation to amyloid-β overproduction during OGD. While the molecular events leading to IL-1β production required JNK and p38MAPK activation, the specific cell types expressing these activated kinases remain to be determined. Astrocytes and neurons, as well as microglia, activate JNK and p38MAPK after ischemia (Wu et al., 2000) and any of these cell types could be involved in a feedforward loop that supports IL-1β release from microglia and postischemic synaptic dysfunction. Interactions established in the study (solid lines) and interactions suggested in previous studies (dashed lines) that could support a feedforward mechanism are shown.
See this image and copyright information in PMC

Comment on

References

    1. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68:19–31. doi: 10.1016/j.neuron.2010.08.023. - DOI - PMC - PubMed
    1. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res. 2007;85:1194–1204. doi: 10.1002/jnr.21252. - DOI - PubMed
    1. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122:1377–1392. doi: 10.1172/JCI58642. - DOI - PMC - PubMed
    1. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS Alzheimer's Disease Cooperative Study. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 2014;82:1536–1542. doi: 10.1212/WNL.0000000000000364. - DOI - PMC - PubMed
    1. Grimmer T, Faust M, Auer F, Alexopoulos P, Förstl H, Henriksen G, Perneczky R, Sorg C, Yousefi BH, Drzezga A, Kurz A. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging. 2012;33:2766–2773. doi: 10.1016/j.neurobiolaging.2012.01.016. - DOI - PubMed

Publication types

Substances

LinkOut - more resources